Relapse/Refratory Peripheral T Cell Lymphoma Clinical Trial
Official title:
Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II, Single-arm, Open-label, Muti-center Study
The purpose of this study is to investigate efficacy and safety of Chidamide Combined With Cyclophosphamide,Prednisone,Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II,Single-arm,Open-label, Muti-center Study
Chidamide is a new histone deacetylase inhibitor and shows anti-tumor activity in
Relapse/Refratory Peripheral T Cell Lymphoma.Cyclophosphamide,Prednisone,Thalidomide(CPT) is
an oral combination regimen for lymphoma patients who can not stand the standard
chemotherapy. The investigators therefore design this open-label,phase II, single-arm trial
to investigate the efficacy of Chidamide Combined With CPT in treatment of fragile Patients
With Relapse/Refratory Peripheral T Cell Lymphoma
Primary Outcome Measures:
• overall response rate
Secondary Outcome Measures:
- duration of response
- progression free survival
- overall survival Enrollment:45 Study Start Date: August 2016 Primary Completion Date:
March 2018
;